Literature DB >> 35707594

Novel Cranial Imaging Findings and a Splice-Site Variant in a Patient with Tyrosinemia Type III, and a Summary of Published Cases.

Ayca Burcu Kahraman1, Halil Tuna Akar1, Naz Güleray Lafcı2, Yılmaz Yıldız1, Ayşegül Tokatlı1.   

Abstract

Tyrosinemia type III is an extremely rare autosomal recessive disease, with only 19 patients yet reported. It is caused by a deficiency of the 4-hydroxyphenylpyruvate dioxygenase enzyme, resulting from biallelic mutations in the HPD gene. Although the clinical spectrum of the disease is not fully known, most patients present with neurodevelopmental symptoms. We report on a 20-month-old patient who was investigated due to developmental delay and dysmorphic features. The girl had a novel splice-site mutation in the HPD gene and ventriculomegaly in cranial imaging, which was not previously associated with tyrosinemia type III. Our patient had mild subjective improvement in social skills and language development after dietary therapy was started and her tyrosine levels decreased. We also summarize clinical, biochemical, and genetic findings of previously published patients with biallelic HPD mutations.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Developmental delay; HPD gene; Metabolic disease; Novel mutation; Tyrosinemia type III

Year:  2022        PMID: 35707594      PMCID: PMC9149457          DOI: 10.1159/000519256

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  18 in total

1.  Against all odds: blended phenotypes of three single-gene defects.

Authors:  Yong Li; Anika Salfelder; Karl Otfried Schwab; Sarah Catharina Grünert; Tanja Velten; Dieter Lütjohann; Pablo Villavicencio-Lorini; Uta Matysiak-Scholze; Bernhard Zabel; Anna Köttgen; Ekkehart Lausch
Journal:  Eur J Hum Genet       Date:  2016-01-27       Impact factor: 4.246

Review 2.  Comprehensive evaluation of the child with intellectual disability or global developmental delays.

Authors:  John B Moeschler; Michael Shevell
Journal:  Pediatrics       Date:  2014-09       Impact factor: 7.124

3.  Tyrosinemia type III: diagnosis and ten-year follow-up.

Authors:  R Cerone; E Holme; M C Schiaffino; U Caruso; L Maritano; C Romano
Journal:  Acta Paediatr       Date:  1997-09       Impact factor: 2.299

Review 4.  Tyrosinemia: a review.

Authors:  P A Russo; G A Mitchell; R M Tanguay
Journal:  Pediatr Dev Pathol       Date:  2001 May-Jun

5.  Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

Authors:  Eva Thimm; Diran Herebian; Birgit Assmann; Dirk Klee; Ertan Mayatepek; Ute Spiekerkoetter
Journal:  Mol Genet Metab       Date:  2010-11-10       Impact factor: 4.797

6.  Tyrosine inhibits creatine kinase activity in cerebral cortex of young rats.

Authors:  Rodrigo Binkowski de Andrade; Tanise Gemelli; Denise Bertin Rojas; Cláudia Funchal; Carlos Severo Dutra-Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2011-07-26       Impact factor: 3.584

7.  Effect of acute administration of L-tyrosine on oxidative stress parameters in brain of young rats.

Authors:  Livia G R P Macêdo; Milena Carvalho-Silva; Gabriela K Ferreira; Júlia S Vieira; Natália Olegário; Renata C Gonçalves; Francieli S Vuolo; Gustavo C Ferreira; Patrícia F Schuck; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Neurochem Res       Date:  2013-10-18       Impact factor: 3.996

8.  Tyrosinemia type III in an asymptomatic girl.

Authors:  Edyta Szymanska; Malgorzata Sredzinska; Elzbieta Ciara; Dorota Piekutowska-Abramczuk; Rafal Ploski; Dariusz Rokicki; Anna Tylki-Szymanska
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

9.  A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation.

Authors:  Reza Najafi; Neda Mostofizadeh; Mahin Hashemipour
Journal:  Adv Biomed Res       Date:  2018-01-22

10.  The mutational constraint spectrum quantified from variation in 141,456 humans.

Authors:  Konrad J Karczewski; Laurent C Francioli; Grace Tiao; Beryl B Cummings; Jessica Alföldi; Qingbo Wang; Ryan L Collins; Kristen M Laricchia; Andrea Ganna; Daniel P Birnbaum; Laura D Gauthier; Harrison Brand; Matthew Solomonson; Nicholas A Watts; Daniel Rhodes; Moriel Singer-Berk; Eleina M England; Eleanor G Seaby; Jack A Kosmicki; Raymond K Walters; Katherine Tashman; Yossi Farjoun; Eric Banks; Timothy Poterba; Arcturus Wang; Cotton Seed; Nicola Whiffin; Jessica X Chong; Kaitlin E Samocha; Emma Pierce-Hoffman; Zachary Zappala; Anne H O'Donnell-Luria; Eric Vallabh Minikel; Ben Weisburd; Monkol Lek; James S Ware; Christopher Vittal; Irina M Armean; Louis Bergelson; Kristian Cibulskis; Kristen M Connolly; Miguel Covarrubias; Stacey Donnelly; Steven Ferriera; Stacey Gabriel; Jeff Gentry; Namrata Gupta; Thibault Jeandet; Diane Kaplan; Christopher Llanwarne; Ruchi Munshi; Sam Novod; Nikelle Petrillo; David Roazen; Valentin Ruano-Rubio; Andrea Saltzman; Molly Schleicher; Jose Soto; Kathleen Tibbetts; Charlotte Tolonen; Gordon Wade; Michael E Talkowski; Benjamin M Neale; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2020-05-27       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.